Tarsus Pharmaceuticals, Inc. (TARS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Tarsus Pharmaceuticals, Inc. (TARS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 46/100 — a percentile rank of Tarsus Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $3.5B |
| P / S | 5.8× |
| EV / EBITDA | -65.8× |
| Gross margin | 93.3% |
| Operating margin | -8.0% |
| Net margin | -7.7% |
| Return on equity | -13.5% |
| ROIC | -26.7% |
| Revenue growth | 105.2% |
| Debt / equity | 0.2× |
| Dividend yield | 0.0% |
Is Tarsus Pharmaceuticals, Inc. overvalued? P/S looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Tarsus Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact